Skip to main content
S&P 5007,773.95+0.66%DOW51,267.90+0.18%NASDAQ27,477.31+1.05%BTC$85,823.00-0.87%ETH$2,714.23-0.50%GOLD$4,166.20+0.23%OIL$89.41-0.02%
Smart Investors Daily
SID Premium
HU

NASDAQ · HURA

TuHURA Biosciences, Inc.

Healthcare · Biotechnology

$1.87

Down-$0.04 (-2.09%)

Updated Oct 6, 2026, 7:46 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
52.85M
P/E ratio
-0.79
Dividend yield
0.00%
52-week range
$0.41 – $3.43
Volume
335.53K
Avg. volume
236.59K

Price performance · HURA

HURA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

HURA closed at $1.87 after 20 trading sessions, down 11.79% for the selected period.

Last close
$1.87
Period change
-11.79%
Period low
$1.87
Period high
$2.18
Daily close
View OHLC price history
HURA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.94$1.94$1.85$1.87335.53K
Oct 2, 2026$2.00$2.0499$1.88$1.91287.78K
Oct 1, 2026$2.09$2.10$1.97$1.98273.6K
Sep 30, 2026$2.06$2.175$2.06$2.10284.47K
Sep 29, 2026$2.08$2.12$2.035$2.07231.3K
Sep 28, 2026$2.06$2.16$2.03$2.09375.39K
Sep 25, 2026$2.14$2.15$2.045$2.10149.26K
Sep 24, 2026$2.04$2.125$2.03$2.10194.49K
Sep 23, 2026$2.10$2.10$2.04$2.05185.52K
Sep 22, 2026$2.17$2.22$2.10$2.13251.79K
Sep 21, 2026$2.06$2.19$2.06$2.18237.22K
Sep 18, 2026$2.11$2.14$2.07$2.10174.75K
Sep 17, 2026$2.05$2.10$2.04$2.09195.83K
Sep 16, 2026$2.03$2.1032$2.01$2.03108.14K
Sep 15, 2026$2.05$2.05$1.98$2.03132.26K
Sep 14, 2026$2.05$2.16$2.05$2.05167.35K
Sep 11, 2026$2.05$2.10$2.04$2.05113.97K
Sep 10, 2026$2.01$2.06$1.98$2.03286.25K
Sep 9, 2026$2.12$2.15$2.00$2.01148.92K
Sep 8, 2026$2.15$2.18$2.05$2.12314.94K

Latest HURA news

The latest Smart Investors Daily articles mentioning HURA.

Stock researchCompany · Overview

HURA research

Overview

Company profile and research snapshot.

Company profile

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
HURA recent ratings
DateFirmRatingTarget
Aug 18, 2026CitizensMarket Outperform—
Apr 27, 2026CitizensMarket Outperform—
Feb 3, 2026HC Wainwright & Co.Buy—
Jan 9, 2026HC Wainwright & Co.Buy—
Nov 14, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

Yahoo · Sep 8, 2026

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By